

Patent  
100848.213102US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231

Inventor: **R. Tam**

Examiner: **H. Owens**

Serial No: **09/624855**

Art Unit: **1623**

Filed: **July 25, 2000**

For: **Specific Modulation of TH1/TH2  
Cytokine Expression by Ribavirin in  
Activated T-Lymphocytes**

**RESPONSE AFTER FINAL**

**Group Art Unit 1623**

Commissioner of Patents  
Alexandria, VA 22313-1450

Dear Sir:

This paper responds to the Final Office Action mailed on May 20, 2003.

**IN THE CLAIMS**

A clean listing of all pending claims following amendment herein is set forth below.

- 1 2/ A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage to promote the Type 1 response and suppress the Type 2 response, wherein the amount of ribavirin added provides a concentration of about 0.25 - 6.7 µg/ml in a medium supporting the lymphocytes.
- 2 4/ A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering